GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Mauna Kea Technologies SA (XPAR:ALMKT) » Definitions » Capex-to-Revenue

Mauna Kea Technologies (XPAR:ALMKT) Capex-to-Revenue : 0.09 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Mauna Kea Technologies Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Mauna Kea Technologies's Capital Expenditure for the six months ended in Dec. 2023 was €-0.32 Mil. Its Revenue for the six months ended in Dec. 2023 was €3.67 Mil.

Hence, Mauna Kea Technologies's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.09.


Mauna Kea Technologies Capex-to-Revenue Historical Data

The historical data trend for Mauna Kea Technologies's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mauna Kea Technologies Capex-to-Revenue Chart

Mauna Kea Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.17 0.14 0.02 0.04

Mauna Kea Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.04 - 0.01 0.09

Competitive Comparison of Mauna Kea Technologies's Capex-to-Revenue

For the Medical Devices subindustry, Mauna Kea Technologies's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mauna Kea Technologies's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mauna Kea Technologies's Capex-to-Revenue falls into.



Mauna Kea Technologies Capex-to-Revenue Calculation

Mauna Kea Technologies's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.382) / 10.48
=0.04

Mauna Kea Technologies's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.315) / 3.665
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mauna Kea Technologies  (XPAR:ALMKT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Mauna Kea Technologies Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mauna Kea Technologies's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mauna Kea Technologies (XPAR:ALMKT) Business Description

Traded in Other Exchanges
Address
9, rue d'Enghien, Paris, FRA, 75010
Mauna Kea Technologies SA is a medical device corporation. It is engaged in designing, developing, and marketing an imaging platform used to view tissues at a cellular level, in real-time, during standard procedures. The firm operates in the business segment of Endomicroscopy. The group's technological platform is Cellvizio which helps physicians to detect early-stage pathologies more accurately and make therapeutic decisions. It generates revenue from the sales of Cellvizio products and accessories used for medical diagnostics, research, and related services. The company sells its products in France and internationally, of which the majority of the revenue is derived from America.

Mauna Kea Technologies (XPAR:ALMKT) Headlines

No Headlines